Short-term corticosteroid use can provide rapid relief of allergy symptoms in dry eye disease

Ophthalmology Times EuropeOphthalmology Times Europe July/August 2022
Volume 18
Issue 06

A short course of a low-dose corticosteroid eye drop can relieve inflammation with only a low increase in intraocular pressure.

Short-term corticosteroid use can provide rapid relief of allergy symptoms in dry eye disease

Dry eye disease (DED) is a multifactorial condition, with the two main pathways being decreased healthy tear production or increased tear evaporation from the ocular surface. If any one of several instigating factors is collectively added, a heightened inflammatory response on the ocular surface can occur, which can affect both DED pathways and lead to the exacerbation of DED.1-4

A dry eye flare is defined as an acute episode of worsening symptoms characterised by inflammation that has disrupted the homeostatic balance within the tear film. This acute worsening of symptoms can last from a few days to a few weeks. Most commonly, a dry eye flare is caused by a trigger that activates a pro-inflammatory cascade on the ocular surface.1-4

Seasonal allergies are likely to trigger an exacerbation or flare of DED symptoms. These patients often complain of runny or teary eyes, redness, itchiness, burning and a gritty sensation, as well as symptoms that affect the adjacent regions such as sinus tenderness and a stuffy, runny nose. 

In my clinical experience, most people have these allergy-induced dry eye flares during the spring and summer when pollen, the biggest inciting factor, is being dispersed by blooming flowers and trees. Along with seasonal allergies, other triggers include perennial allergens (such as pet dander, dust and mould); excessive screen time; excessive wearing of contact lenses; and vented air from heat or air conditioning.5-13 

Dry eye flare: What to look for

When Ieducate patients about dry eye flares, I let them know that a flare is a symptomaticacute episode during apreviously quiescent period. Many of my patients with more severe dry eye are on baseline therapysuch as ciclosporinor lifitegrastophthalmic solution (Xiidra,Novartis), and for the most part, their symptoms are well controlled.

However, when a trigger such as seasonal allergyinduces a pro-inflammatory state, they develop a sudden onset of acute symptoms.In other words, these patients are quite miserable. They do not say: “Doctor, I think I’m experiencing a dry eye flare,” but they do say “My medications don’t seem to be working anymore, and I’m getting these symptoms again." So, I take the opportunity to educate them, reminding them that althoughthere is no cure for DED, we can manage it with therapy and that it is normal to experience fluctuations in symptoms.

I say: “Your seasonal allergies are pushing your eyes into overdrive or a pro-inflammatory state, and medication is needed to control this acute flare.” Treatment with an approved, fast-acting, low-dose topical corticosteroid can provide rapid relief of symptoms—exactly what these patients are looking for.

How to treat this

Loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis, Kala Pharmaceuticals) isthe first United States Food and Drug Administration-approved corticosteroid for short-term treatment of the signs and symptoms associated with DED. The drop has a novel formulation that utilises Ampplify, Kala’s proprietary mucus-penetrating particle technology.

Nanoparticles of approximately 300 nmin diameter are coated to facilitate their penetration through the mucus barrier. This controlled delivery system enables the drop to spread more uniformly across the ocular surface.

I like to use this dropin patients with DED because the quick onset of action means noticeable, rapid relief, plus the patients only need to use it for a short period of time—no more than 2 weeks. Those patients with DED who are on chronic medication can continue while supplementing with loteprednol etabonate ophthalmic suspension 0.25%. 

Patients should be educated that seasonal changesor other triggers mentioned earlier may cause them to have recurrent episodes of dry eye flares that need to be treated with a short course of a low-dose corticosteroid. Many of us worry about intraocular pressure (IOP) elevation secondary to corticosteroid use. I reassure patients that the drop has a favourableadverseeffect profile and that because of its low concentration, I am comfortable with episodic dosing throughout the year.

In fact, loteprednol etabonate ophthalmic suspension 0.25% was studied in more than 2,800 patients with DED.14-16 The drop was well tolerated and, similar to the vehicle, illustrated a low incidence of IOP increase. 

In the treatment and vehicle groups, respectively, 0.2% and 0% of subjects experienced an equal-to or greater-than-10 mm Hg increase from baseline, resulting in an IOP measurement of equal-to or greater-than-21 mm Hg at any post-baseline visit up to 29 days.These IOP safety data provide me with a boost in confidenceto prescribe this drop to my patients with DED.

For compliant patients with DED who have a good understanding of the disease, I have them keep their loteprednol etabonate ophthalmic suspension 0.25% handy andI advise them to re-start it for a short course when they notice a dry eye flare.

It is normal for patients to experience multiple flares throughout the year. For some, it may be more (or less) frequent. These inflammatory spikes of acute exacerbation occur in approximately eight out of ten patients with dry eye, and approximately half of patients with DED experience flares only, without continuous symptoms, four to six times per year.17-20

Antihistamine use and contact lens wear

Many allergy patients aretaking oral antihistamines. If I see that they are having signs and symptoms of ocular surface disease, I tell them to hold off on their oral antihistamine because the drugcan worsen DED.

Depending on the severity of their systemic allergy symptoms, I may talk to their allergy specialist to determine if they can switch to a nasal decongestant or other non-systemic therapy. The best solution, though, is always to avoid the allergy trigger and make other appropriate environmental and/or lifestyle changes.

I advise contact lens wearers to discontinue use when they are experiencing a dry eye flare. I prefer that they do not use eye drops with contact lenses, to avoid problems such as build-up, debris or denaturing of the lens material. In addition, lens wear can add to, or be a culprit of, their dry eye flare due to the mechanical rubbing on their eyes and oxygen deprivation.

While they take a contact lens holiday, they can also start a short course of loteprednol etabonate ophthalmic suspension 0.25% for rapid relief of their symptoms. They can then consider slowly going back to using their contact lenses; however, I recommend decreasing wear time as much as possible (so that it totals no more than 8 hours per day). In addition, we should always ensure that patients are wearing lenses with optimal oxygen permeability, with daily disposables as an ideal option.

Stay ahead of the game

For most of our patients with DED, it is not a matter of if, but when, they will have an acute exacerbation of symptoms—dry eye flares. Fortunately, we have a fast-acting treatment to lessen their misery.

Dagny Zhu, MD
Dr Dagny Zhu is a cornea, cataract and refractive surgeon and medical director and partner at Nvision Eye Center in Rowland Heights, California, US. Her website is Dr Zhu declared that she hasno financial interest in the products or companies mentioned.
1. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124:S4-S13.
2. Lienert JP, Tarko L, Uchino M, et al. Long-term natural history of dry eye disease from the patient’s perspective. Ophthalmology. 2016;123:425-433.
3. Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. Exp Eye Res. 2020;201:108294.
4. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf.2017;15:276-283.
5. Rolando M, Zierhut M, Barabino S. Should we reconsider the classification of patients with dry eye disease? Ocul Immunol Inflamm. 2021;29:521-523.
6. Amparo F, Dana R. Web-based longitudinal remote assessment of dry eye symptoms. Ocul Surf.2018;16:249-253.
7. Iyer JV, Lee SY, Tong L. The dry eye disease activity log study. ScientificWorldJournal.2012;2012:589875.
8. Karakus S, Agrawal D, Hindman HB, et al. Effects of prolonged reading on dry eye. Ophthalmology.2018;125:1500-1505.
9. Kim Y, Paik HJ, Kim MK, et al. Short-term effects of ground-level ozone in patients with dry eye disease: a prospective clinical study. Cornea.2019;38:1483-1488.
10. Ousler GW 3rd, Rimmer D, Smith LM, et al. Use of the controlled adverse environment (CAE) in clinical research: a review. OphthalmolTher. 2017;6:263-276.
11. López-Miguel A, Tesón M, Martín-Montañez V, et al. Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental conditions. Am J Ophthalmol.2014;157:788-798.e2.
12. Tesón M, González-García MJ, López-Miguel A, et al. Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease. InvestOphthalmol Vis Sci.2013;54:2093-2099.
13. Fernández I, López-Miguel A, Enríquez-de-Salamanca A, et al. Response profiles to a controlled adverse desiccating environment based on clinical and tear molecule changes. Ocul Surf.2019;17:502-515.
14. Gupta PK, Venkateswaran N. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares. Ther Adv Ophthalmol. 2021;13:25158414211012797.
15. Korenfeld M, NIchols KK, Goldber D, et al. Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease. Cornea. 2021;40:564-570.
16. Holland E, Nichols KK, Foulks GN, et al. Safety and efficacy of KPI-121 ophthalmic suspension 0.25% for DED in four RCTs. Paper presented at: American Academy of Ophthalmology 2020 Annual Meeting. 13-15 Nov 2020; virtual.
17. Brazzell RK, Zickl L, Farrelly J, et al. Prevalence and characteristics of dry eye flares: a patient questionnaire survey. Paper presented at: American Academy of Ophthalmology 2019 Annual Meeting. 12-15 Oct 2019; San Francisco, California, US.
18. Brazzell RK, Zickl L, Farrelly J, et al. Prevalence and characteristics of symptomatic dry eye flares: results from patient questionnaire surveys. Poster presented at: American Academy of Optometry98th Annual Meeting. 23-27October 2019; Orlando, Florida, US.
19. 2018 study of dry eye sufferers. Conducted by Multi-sponsor Surveys Inc. Accessed 10 Jun 2022.
20. 2021 study of dry eye sufferers. Conducted by Multi-sponsor Surveys Inc.Accessed 10 Jun 2022.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.